Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes (Q34886311)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes |
scientific article |
Statements
1 reference
Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes (English)
1 reference
A Garber
1 reference
R R Henry
1 reference
R Ratner
1 reference
P Hale
1 reference
C T Chang
1 reference
B Bode
1 reference
LEAD-3 (Mono) Study Group
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference